Revenue recognition and accounts receivable (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Revenue Recognition And Accounts Receivable [Abstract] |
|
| Schedule of Net Sales by Product Category and Reporting Segment |
The tables below present net sales by product category and reporting segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2026 |
|
|
2025 |
|
|
Change |
|
Therapeutic Solutions |
|
$ |
64,152 |
|
|
$ |
62,573 |
|
|
|
2.5 |
% |
Spinal Implants, Biologics, and Enabling Technologies |
|
|
109,091 |
|
|
|
107,251 |
|
|
|
1.7 |
% |
Global Spine |
|
|
173,243 |
|
|
|
169,824 |
|
|
|
2.0 |
% |
Global Limb Reconstruction |
|
|
37,690 |
|
|
|
33,297 |
|
|
|
13.2 |
% |
Net sales |
|
$ |
210,933 |
|
|
$ |
203,121 |
|
|
|
3.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended June 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2026 |
|
|
2025 |
|
|
Change |
|
Therapeutic Solutions |
|
$ |
121,926 |
|
|
$ |
117,623 |
|
|
|
3.7 |
% |
Spinal Implants, Biologics, and Enabling Technologies |
|
|
215,169 |
|
|
|
216,037 |
|
|
|
-0.4 |
% |
Global Spine |
|
|
337,095 |
|
|
|
333,660 |
|
|
|
1.0 |
% |
Global Limb Reconstruction |
|
|
70,546 |
|
|
|
63,107 |
|
|
|
11.8 |
% |
Net sales |
|
$ |
407,641 |
|
|
$ |
396,767 |
|
|
|
2.7 |
% |
|
| Schedule of Components Net Sales |
The table below presents product sales and marketing service fees, which are both components of net sales:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Product sales |
|
$ |
199,979 |
|
|
$ |
191,395 |
|
|
$ |
386,095 |
|
|
$ |
373,028 |
|
Marketing service fees |
|
|
10,954 |
|
|
|
11,726 |
|
|
|
21,546 |
|
|
|
23,739 |
|
Net sales |
|
$ |
210,933 |
|
|
$ |
203,121 |
|
|
$ |
407,641 |
|
|
$ |
396,767 |
|
|
| Allowances for Expected Credit Losses |
The following table provides the detail of changes in the Company's allowance for expected credit losses for the three and six months ended June 30, 2026, and 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
(Unaudited, U.S. Dollars, in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Allowance for expected credit losses beginning balance |
|
$ |
8,990 |
|
|
$ |
8,602 |
|
|
$ |
8,308 |
|
|
$ |
7,418 |
|
Current period provision for expected credit losses |
|
|
2,872 |
|
|
|
779 |
|
|
|
3,591 |
|
|
|
1,837 |
|
Write-offs charged against the allowance and other |
|
|
(1,254 |
) |
|
|
(747 |
) |
|
|
(1,259 |
) |
|
|
(758 |
) |
Effect of changes in foreign exchange rates |
|
|
(45 |
) |
|
|
275 |
|
|
|
(77 |
) |
|
|
412 |
|
Allowance for expected credit losses ending balance |
|
$ |
10,563 |
|
|
$ |
8,909 |
|
|
$ |
10,563 |
|
|
$ |
8,909 |
|
|